4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.79−0.50 (-4.43%)
Close on Nov 17, 2026Market cap $778.82MP/E –Yield –
4D Molecular Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
4D Molecular Therapeutics's price to sales ratio was 7.8× on Nov 11, 2026, against 24.7× a year earlier. Over the last 3 years it ranged from 5.9× to 396.8×, with a median of 31.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.8× | −25.7 |
| 2024 | Jan 31, 2024 | 33.5× | −5.9 |
| 2023 | Dec 29, 2023 | 39.4× | −325.2 |
| 2022 | Dec 30, 2022 | 364.6× | +333.2 |
| 2021 | Jan 29, 2021 | 31.4× | +0.7 |
| 2020 | Dec 31, 2020 | 30.7× | – |
See a number that looks wrong?